Dabrafenib + Trametinib + Hydroxychloroquine

Phase 1/2Active

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Low Grade Glioma (LGG) of Brain With BRAF Aberration

Conditions

Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1

Trial Timeline

Jan 17, 2020 → Mar 31, 2026

NCT ID

NCT04201457

About Dabrafenib + Trametinib + Hydroxychloroquine

Dabrafenib + Trametinib + Hydroxychloroquine is a phase 1/2 stage product being developed by Brain Biotech for Low Grade Glioma (LGG) of Brain With BRAF Aberration. The current trial status is active. This product is registered under clinical trial identifier NCT04201457. Target conditions include Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04201457	Phase 1/2	Active	Jan 17, 2020	Mar 31, 2026	Low Grade Glioma (LGG) of Brain With BRAF Aberration

Competing Products

20 competing products in Low Grade Glioma (LGG) of Brain With BRAF Aberration

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	25
azenosertib	Zentalis Pharmaceuticals	Phase 2	44
Sepantronium Bromide	Cothera Bioscience	Phase 2	44
DS-1001b	Daiichi Sankyo	Phase 2	52
Rabeprazole Sodium	Eisai	Pre-clinical	23
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	52
Abemaciclib + Letrozole	Eli Lilly	Phase 2	52
Pirtobrutinib + Mosunetuzumab	Eli Lilly	Phase 2	52
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	33
DSP-0390	Sumitomo Pharma	Phase 1	33
Mirvetuximab soravtansine + Carboplatin	AbbVie	Phase 2	52
Mirvetuximab Soravtansine	AbbVie	Phase 2	52
Acalabrutinib + Obinutuzumab	AstraZeneca	Phase 2	52
Olaparib Pill + AZD6738	AstraZeneca	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Efineptakin alfa + Pembrolizumab	Merck	Phase 2	52
Pembrolizumab	Merck	Phase 2	52
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel	Merck	Phase 2	52
Cilengitide	Merck	Phase 2	52
Avelumab	Merck	Phase 2	52

Other Products from Brain Biotech

FCYC+Conventional treatment + conventional treatmentApproved

Escitalopram + PlaceboApproved

Sinemet CR + Placebo oral capsuleApproved

MethylprednisoloneApproved

MethylphenidateApproved